
William Nelson
Articles
-
Sep 20, 2024 |
cancertodaymag.org | William Nelson
ANTIBODIES THAT CAN SIMULTANEOUSLY BIND both to cancer cells and to immune cells—some of them given the trademarked name BiTEs, for bispecific T-cell engagers, by the biopharmaceutical firm Amgen—make up a growing collection of anticancer drugs that act to bring cytolytic T cells, the kind of immune cell that can kill cancer cells, near the target cancer cells.
-
Aug 27, 2024 |
nature.com | Mindy K Graham |Rulin Wang |Roshan Chikarmane |Polina Sysa-Shah |Xin Pan |Yan Zhang | +5 more
AbstractHow prostate cancer cells and their precursors mediate changes in the tumor microenvironment (TME) to drive prostate cancer progression is unclear, in part due to the inability to longitudinally study the disease evolution in human tissues.
-
Jul 26, 2024 |
medium.com | William Nelson
Introduction: Welcome to the ultimate guide on gaining free Onthis through airdrops. If you want to expand your crypto assets without investing, you're in the right place. This guide will guide you in claiming the exciting airdrop on DappRadar, starting your journey into the world of Onthis airdrops. Participating in Onthis Airdrops: In the world of cryptocurrency, participating in airdrops is a frequent way for projects to distribute tokens to the community.
-
Jul 24, 2024 |
medium.com | William Nelson
ConnectKit airdrops are basically free tokens allocated by new or existing blockchain projects to showcase their initiatives or token circulation. Platforms like DappRadar have optimized the process, enabling than ever to claim these airdrops. Why bother, you ask? Because apart from getting free tokens, you're also getting a front-row seat to groundbreaking new crypto projects and innovations.
-
Jun 21, 2024 |
cancertodaymag.org | William Nelson
THE CENTERS FOR DISEASE CONTROL AND PREVENTIONestimates that nearly 42% of U.S. adults are obese, up from 30% at the dawn of the new millennium. By 2030, the global burden of obesity will climb to more than a billion adults. Obesity likely contributes to poorer outcomes for patients with cancers of the breast, prostate, colon and rectum, uterus, liver, kidney and pancreas. It is responsible for as much as a 17% increased risk of cancer mortality.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →